The Plasma Levels of ADAMTS-13, von Willebrand Factor, VWFpp, and Fibrin-Related Markers in Patients With Systemic Sclerosis Having Thrombosis

Koji Habe, MD, PhD¹, Hideo Wada, MD, PhD², Ayaka Higashiyama, MD¹, Tomoko Akeda, MD, PhD¹, Kenshiro Tsuda, MD, PhD¹, Ryoko Mori, MD, PhD¹, Masato Kakeda, MD, PhD¹, Takeshi Matsumoto, MD, PhD³, Kohshi Ohishi, MD, PhD³, Keiichi Yamanaka, MD, PhD¹, Naoyuki Katayama, MD, PhD⁴, and Hitoshi Mizutani, MD, PhD¹

Abstract
This study aimed to examine the hemostatic abnormalities in patients with systemic sclerosis (SSc) and the relationship between these abnormalities and thrombotic events (THEs), focusing on the difference in diffuse cutaneous SSc (dcSSc) and limited cutaneous SSc (lcSSc). The plasma levels of ADAMTS-13 (a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13), von Willebrand factor (VWF), VWF propeptide (VWFpp), D-dimer, and soluble fibrin (SF) were measured in 233 patients with SSc. The relationship between their levels and organ involvement, including THEs and interstitial lung disease (ILD), was evaluated. The plasma levels of VWF and VWFpp were significantly elevated and ADAMTS-13 activity was significantly decreased in patients with SSc compared to healthy participants. The VWFpp in dcSSc was significantly higher than in lcSSc. Twelve patients with SSc were complicated with acute THE, and 25 patients with SSc were complicated with past THE. The plasma levels of D-dimer and SF were significantly elevated in patients with SSc having THE. The plasma levels of VWF and VWFpp were significantly elevated in patients with SSc having ILD. The plasma levels of D-dimer were elevated in patients with SSc having other connective tissue diseases (CTDs). The plasma levels of ADAMTS-13 were significantly decreased and VWF, VWFpp, and SF were increased in patients with a D-dimer level of ≥1 µg/mL. Systemic sclerosis carries a high risk of THE, especially in patients with other CTDs. Plasma hemostasis-related markers are closely related to ILD and THE. These markers are important as markers of organ involvement as well as THE.

Keywords
systemic sclerosis, VWF, VWFpp, ADAMTS-13, D-dimer, soluble fibrin

Introduction
Connective tissue diseases (CTDs), especially systemic lupus erythematosus (SLE),¹ are well known to be accompanied by a high-risk disease of developing various thrombotic events (THEs), including deep vein thrombosis (DVT), pulmonary embolism (PE), cerebral thrombosis, acute coronary syndrome, and thrombotic microangiopathy (TMA).² While the reported frequency of THEs is low in non-SLE CTD patients, including those with systemic sclerosis (SSc),³ the risk of THEs in patients with SSc is still higher than in non-SSc individuals.⁴⁶ Indeed, cardiovascular disease accounts for 20% to 30% of all SSc deaths.⁷ Various biomarkers of inflammation, thrombophilia, and organ dysfunction have been identified in patients with SSc.⁸⁻¹² It is also known that around half of patients with SSc having renal crisis develop TMA.¹³

¹ Department of Dermatology, Mie University Graduate School of Medicine, Mie, Tsu, Japan
² Department of Molecular and Laboratory Medicine, Mie University Graduate School of Medicine, Mie, Tsu, Japan
³ Department of Blood Transfusion, Mie University Graduate School of Medicine, Mie, Tsu, Japan
⁴ Department of Hematology and Oncology, Mie University Graduate School of Medicine, Mie, Tsu, Japan

Corresponding Author:
Hideo Wada, Department of Molecular and Laboratory Medicine, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan.
Email: wadahide@clin.medic.mie-u.ac.jp

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
ADAMTS-13, a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13, cleaves unusual large multimers of von Willebrand factor (VWF) to inhibit the pathological activation of platelets. Thrombotic thrombocytopenic purpura, caused by a severe deficiency of ADAMTS-13, is a major complication in CTD and causes around 20% of TMA in patients with CTD. The serum levels of the vascular endothelial cell injury markers VWF, VWF propeptide (VWFpp), and thrombomodulin (TM) are elevated in patients with TMA or disseminated intravascular coagulation.

As we reported previously, the plasma levels of VWF and VWFpp are elevated in patients with SSc and antiphospholipid antibody syndrome (APS), suggesting the presence of vascular endothelial cell injury. In the present study, we measured the plasma levels of ADAMTS-13, VWF, VWFpp, and several other hemostatic biomarkers in 233 patients with SSc and evaluated the relationship between these hemostatic biomarkers and several manifestations of SSc, including the spread of skin involvement, THE, interstitial lung disease (ILD), and complication of other CTDs.

### Materials and Methods

The patients who consulted the clinics of dermatology or hematology at Mie University Hospital from January 1, 1994, to December 31, 2016, were enrolled in the present study. We diagnosed SSc according to the 2013 Classification Criteria for Systemic Sclerosis (American College of Rheumatology/European League Against Rheumatism [ACR/EULAR]) and classified patients as having limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc) based on the definition of LeRoy and Medsger. Systemic lupus erythematosus was diagnosed by the 1997 update of the 1982 American College of Rheumatology Revised Criteria for Classification of Systemic Lupus Erythematosus. Dermatomyositis and polymyositis were diagnosed based on the criteria of Bohan and Peter. Sjögren syndrome was diagnosed based on the 2012 American College of Rheumatology Classification Criteria for Sjögren Syndrome. Rheumatoid arthritis was diagnosed based on the 2010 Rheumatoid Arthritis Classification Criteria: ACR/EULAR. As controls, healthy volunteers matched for age and sex were randomly selected.

Thrombosis was diagnosed based on the clinical manifestations and was confirmed by appropriate clinical and radiological examinations. The presence of PE and DVT was diagnosed by a whole-leg compression ultrasound examination and/or contrast computed tomography (CT). Cerebral and other organ thromboses were diagnosed by CT or magnetic resonance imaging. Thrombotic events diagnosed within 3 days after the onset were classified as acute THE. Thrombosis that developed more than a month before was classified as past THE. The presence of ILD was defined by the radiology reports: the presence of any ground-glass appearance, fibrotic interstitial changes, or honeycombing. ILD was then confirmed by high-resolution CT.
The plasma samples were prepared as reported previously. In brief, plasma was separated using a 0.38% sodium citrate preparation with 3000g centrifugation at 4°C for 15 minutes. The plasma was stored at −80°C until use. The ADAMTS-13 activity was measured by Kokame method using a FRETS-VWF73 peptide (Peptide Institute, Inc, Osaka, Japan). The plasma levels of VWF and VWFpp were measured by a VWF & Propeptide assay kit (GTI Diagnostics, Waukesha, Wisconsin). The plasma levels of soluble fibrin (SF) and D-dimer were measured by 2 latex agglutination methods using IATRO-SF and LPIA-ACE D-Dimer II (LSI Medience Corporation, Tokyo, Japan), respectively. The plasma level of TM was measured by a chemiluminescent enzyme immunoassay using STACIA CLEIA TM (LSI Medience Corporation). The tricuspid regurgitation pressure gradient (TRPG) was measured using cardiac ultrasound.

The study protocol was approved by the human ethics review committee of Mie University School of Medicine (approval number: 2629), and informed consent was obtained from all the patients. This study was carried out in accordance with the principles of the Declaration of Helsinki.

Statistical Analyses
The results were expressed as the median (25th-75th percentiles). Differences between groups were analyzed using the Mann-Whitney U test. P values of <.05 were considered to indicate a statistically significant difference. The significance of a frequency was examined by the χ² test. All statistical analyses were performed using the SPSS Statistics software program (version 22; IBM, New York, New York).

Figure 1. A, Plasma ADAMTS-13 activity in systemic sclerosis (SSc) and healthy volunteers. B, Plasma von Willebrand factor (VWF) levels in SSc and healthy volunteers. C, Plasma von Willebrand factor propeptide (VWFpp) levels in SSc and healthy volunteers. ***P < .001 (Mann-Whitney U test).
Results

The laboratory data of 233 patients with SSc were serially investigated, including 173 patients with lcSSc (mean age, 64.5 [11.7] years) and 60 patients with dcSSc (mean age, 68.0 [11.3] years), as shown in Table 1. All of the patients developed in lcSSc and dcSSc are shown in Table 2. In patients with SSc, the plasma levels of ADAMTS-13 were significantly decreased and the plasma levels of VWF and VWFpp were significantly elevated compared to those of healthy controls \((P < .001; \text{Figure } 1A-C)\).

Between patients with lcSSc and dcSSc, no significant difference was detected in values of ADAMTS-13, VWF, D-dimer, SF, TM/estimated glomerular filtration rate (eGFR), or TRPG. However, the plasma levels of VWFpp and eGFR were significantly higher in patients with dcSSc than in those with lcSSc \((P < .05)\). There were no significant differences in the risk of acute THE or past THE between lcSSc and dcSSc \((P > .05)\) (Table 3).

The plasma levels of D-dimer and SF in patients with SSc with THE were significantly higher than those in patients without THE \((P < .001 \text{ and } P < .01, \text{respectively})\). The C-reactive protein (CRP), lactate dehydrogenase (LDH), prothrombin time (PT), and activated partial thromboplastin time (APTT) also showed significant difference between patients having SSc with and without THE (Table 4).

The prevalence of ILD in patients with dcSSc was significantly higher than in those with lcSSc, in concordance with previous findings \((P < .001; \text{Table } 3)\). Surprisingly, the plasma levels of VWF and VWFpp were significantly higher in the patients with SSc with ILD than in those without ILD \((P < .05)\).

In patients with SSc having other CTDs, the plasma levels of VWF and VWFpp in patients with SSc with ILD were significantly high than in those without ILD \((P < .05; \text{Table } 5)\).

The plasma D-dimer level of patients having SSc with other CTDs was significantly higher than that of patients having SSc without other CTDs \((P < .05; \text{Table } 6)\). The plasma level of ADAMTS-13 was significantly lower in patients with SSc having a high D-dimer level \((>1 \text{ mg/mL})\) than in those with a low D-dimer level \((<1 \text{ mg/mL})\). Interestingly, patients with a high D-dimer level \((>1 \text{ mg/mL})\) showed higher VWF, VWFpp, SF, LDH, and CRP levels as well as daily and total corticosteroid doses and duration than patients with a low D-dimer level \((<1 \text{ mg/mL})\). In contrast, the TM/eGFR, eGFR, TRPG, age, PT, APTT, and immunoglobulin G titer showed no significant difference between the low and high D-dimer groups (Table 7).

Discussion

Systemic sclerosis induces systemic inflammation followed by severe vascular lesions of small arteries, smooth muscle involvement of digestive systems, and collagen deposition in skin, lung, and various internal organs. Clinically, typical skin lesions, including digital ulcers, nail fold capillary thrombosis, and digital pitting scars, are suggestive of the presence of ischemic vascular changes and hemostatic and/or coagulation abnormalities. In general, these changes are more apparent in dcSSc than in lcSSc.

However, in contrast to arterial vascular changes, the venous abnormalities associated with SSc have not been fully investigated. The incidence of venous thromboembolism (VTE) per

| Table 3. A Comparison Between LcSSc and DcSSc. | \(n = 233\) (F/M, 211/22) |
|-----------------|-----------------|-----------------|
|                | lcSSc (n = 173) | dcSSc (n = 60)  | \(P\) Value  |
| Age, years, mean (SD) | 64.5 (11.7) | 68.0 (11.3) | .76 |
| F/M              | 158/15         | 53/7           | .61 |
| SSc              |                |                | .90 |
| SSc without other CTD | 113            | 39             | .76 |
| SSc with other CTD | 60             | 21             | .74 |
| THE in study     |                |                | 1.0 |
| Acute THE       | 10             | 2              | .68 |
| Past THE        | 19             | 6              | .68 |
| Total           | 29             | 8              | .68 |
| ILD             | 25             | 25             | <.001 |
| ADAMTS-13 (%)   | 80.66 (60.76, 97.91) | 87.29 (66.98, 98.87) | .10 |
| VWF, U/dL       | 140 (95, 162)  | 138 (114, 199) | .33 |
| VWFpp, U/dL     | 114 (85, 157)  | 128 (111, 159) | .049 |
| D-dimer, µg/mL  | 0.52 (0.32, 1.39) | 0.53 (0.35, 1.43) | .83 |
| Soluble fibrin, µg/mL | 1.00 (0.30, 3.00) | 0.40 (0.30, 2.60) | .13 |
| TM/eGFR, mL/minute/1.73 m² | 0.1843 (0.1337, 0.2370) | 0.1596 (0.1013, 0.2227) | .097 |
| eGFR, mL/minute/1.73 m³ | 72.2 (60.3, 83.5) | 81.2 (66.6, 90.2) | .016 |
| TRPG, mm Hg     | 20 (17, 26)    | 21 (18, 23)    | .26 |

Abbreviations: CTD, connective tissue disease; dcSSc, diffuse cutaneous SSc; eGFR, estimated glomerular filtration rate; F, female; ILD, Interstitial lung disease; lcSSc, limited cutaneous SSc; M, male; SD, standard deviation; SSc, systemic sclerosis; THE, thrombotic event; TM, thrombomodulin; TRPG, tricuspid regurgitation pressure gradient; VWF, von Willebrand factor; VWFpp, von Willebrand factor propeptide.

*aThe data are presented as the median (Q1, Q3).
1000 person-years was reported to be 6.56 in patients with SSc, and the multivariable hazard ratio for VTE among patients with SSc was 3.47 in comparison to non-SSc patients. Interestingly, the present study noted the development of acute THE in 5.8% of patients with lcSSc and 3.3% of patients with dcSSc and past THE in 11.0% of patients with lcSSc and 10.0% of patients.

**Table 4. A Comparison Between Patients Having SSc With and Without THE.**

|                      | Without THE: n = 196 | With THE: n = 37 | P Value |
|----------------------|----------------------|------------------|---------|
| lcSSc/dcSSc          | 144/52               | 21/16            | .49     |
| ILD                  | 40                   | 10               | .39     |
| Age, years           | 65.0 (58.0, 73.0)     | 67.0 (60.5, 76.0) | .17     |
| ADAMTS-13, %         | 85.49 (63.76, 99.15) | 78.32 (37.50, 95.38) | .17 |
| VWF, U/dL            | 136 (96, 165)        | 144 (128, 164)   | .43     |
| VWFpp, U/dL          | 118 (87, 156)        | 145 (98, 195)    | .077    |
| D-dimer, µg/mL       | 0.50 (0.31, 1.07)    | 2.39 (0.73, 6.69) | <.001   |
| Soluble fibrin, µg/mL| 0.70 (0.30, 3.00)    | 3.75 (0.30, 21.80) | .0040   |
| TM/eGFR, ng/mL²/min/1.73 m² | 0.1770 (0.1222, 0.2338) | 0.1877 (0.1402, 0.2331) | .86 |
| eGFR, ml/min/1.73 m² | 75.4 (63.7, 87.2)    | 68.5 (57.7, 78.5) | .072    |
| TRPG, mm Hg          | 20 (17, 25)          | 21 (20, 25)      | .55     |
| PT, seconds          | 11.5 (10.8, 12.1)    | 11.8 (11.1, 13.4) | .015    |
| APTT, seconds        | 29.4 (27.0, 31.6)    | 30.1 (28.3, 35.6) | .039    |
| CRP, mg/dL           | 0.080 (0.030, 0.38)  | 0.18 (0.040, 1.76) | .047    |
| LDH, IU/L            | 201 (178, 235)       | 235 (206, 320)   | .0020   |
| IgG, mg/dL           | 1256 (1095, 1555)    | 1291 (1008, 1651) | .95     |

**Abbreviations:** APTT, activated partial thromboplastin time; CRP, C-reactive protein; dcSSc, diffuse cutaneous SSc; eGFR, estimated glomerular filtration rate; F, female; IgG, immunoglobulin G; ILD, Interstitial lung disease; lcSSc, limited cutaneous SSc; LDH, Lactate dehydrogenase; M, male; PT, prothrombin time; SSc, systemic sclerosis; THE, thrombotic event; TM, thrombomodulin; TRPG, tricuspid regurgitation pressure gradient; VWF, von Willebrand factor; VWFpp, von Willebrand factor propeptide.

**Table 5. A Comparison Between Patients Having SSc With and Without ILD.**

|                      | Without ILD | With ILD | P Value |
|----------------------|-------------|----------|---------|
| All SSc              | ADAMTS-13, %| 83.11 (62.08, 99.65) | 86.24 (61.25, 97.34) | .52     |
| VWF, U/dL            | 132 (94, 162) | 154 (132, 208) | .013    |
| VWFpp, U/dL          | 114 (84, 157) | 133 (109, 171) | .028    |
| D-dimer, µg/mL       | 0.51 (0.31, 1.18) | 1.20 (0.36, 2.63) | .052    |
| Soluble fibrin, µg/mL| 0.90 (0.30, 3.00) | 0.50 (0.30, 3.00) | .63     |
| TM/eGFR, ng/mL²/min/1.73 m² | 0.1817 (0.1192, 0.2327) | 0.1600 (0.1412, 0.2801) | .98 |
| eGFR, ml/min/1.73 m² | 75.6 (64.4, 88.2) | 70.3 (61.1, 79.2) | .050    |
| TRPG, mm Hg          | 21 (17, 25) | 20 (17, 22) | .57     |
| SSc without other CTD| ADAMTS-13, %| 85.41 (62.58, 102.92) | 86.24 (64.36, 97.42) | 1.0     |
| VWF, U/dL            | 135 (90, 162) | 151 (118, 163) | .23     |
| VWFpp, U/dL          | 114 (83, 157) | 117 (107, 147) | .56     |
| D-dimer, µg/mL       | 0.50 (0.29, 1.05) | 0.76 (0.34, 1.97) | .14     |
| Soluble fibrin, µg/mL| 0.90 (0.30, 3.00) | 0.85 (0.30, 3.50) | .79     |
| TM/eGFR, ng/mL²/min/1.73 m² | 0.1822 (0.1169, 0.2407) | 0.1603 (0.1380, 0.2839) | .83 |
| eGFR, ml/min/1.73 m² | 76.3 (65.0, 87.8) | 71.1 (62.6, 79.6) | .15     |
| TRPG, mm Hg          | 21 (17, 25) | 19 (15, 26) | .47     |
| SSc with other CTD   | ADAMTS-13, %| 82.78 (55.23, 90.18) | 84.78 (68.92, 97.28) | .28     |
| VWF, U/dL            | 129 (93, 160) | 166 (136, 190) | .015    |
| VWFpp, U/dL          | 112 (84, 157) | 152 (125, 192) | .018    |
| D-dimer, µg/mL       | 0.62 (0.43, 1.51) | 1.23 (0.41 - 3.17) | .32     |
| Soluble fibrin, µg/mL| 0.90 (0.30, 3.00) | 0.50 (0.30, 5.08) | .72     |
| TM/eGFR, ng/mL²/min/1.73 m² | 0.1808 (0.1266, 0.2192) | 0.1490 (0.09376, 0.2638) | .91 |
| eGFR, ml/min/1.73 m² | 74.8 (60.1, 89.0) | 68.8 (57.5, 79.9) | .23     |
| TRPG, mm Hg          | 20 (18, 22) | 21 (19, 22) | .76     |

**Abbreviations:** CTD, connective tissue disease; eGFR, estimated glomerular filtration rate; ILD, Interstitial lung disease; SSc, systemic sclerosis; TM, thrombomodulin; TRPG, tricuspid regurgitation pressure gradient; VWF, von Willebrand factor; VWFpp, von Willebrand factor propeptide.

*The data are presented as the median (Q1, Q3).*
with dcSSc. This suggests a high risk of THE in SSc. Surprisingly, the prevalence of THE showed no marked difference between patients with lcSSc and dcSSc. This implies the presence of other factors related to THE in patients with SSc. The overlap of other CTDs is common in patients with SSc, and CTDs other than SSc, especially SLE, induce the development of various THEs more often than does SSc. The present study revealed an increase in the THE risk by the overlap of CTDs complicating hemostatic abnormalities.

Patients with SSc showed lower plasma levels of ADAMTS-13 and higher plasma levels of VWF and VWFpp than healthy participants, suggesting that high coagulability exists in patients with SSc. The plasma levels of d-dimer and SF were high in patients with THE, suggesting that SSc may be a causative condition for THE. Soluble fibrin has a shorter half-life than d-dimer, and d-dimer is a more sensitive marker for clinical diagnosis for THE. A d-dimer level of ≥1 μg/mL has been proposed as a hallmark for a prethrombotic state. A d-dimer level of ≥1 μg/mL was lower and plasma levels of VWF and VWFpp were higher in patients with SSc having high D-dimer levels (>1 μg/mL) than in those with low d-dimer levels (<1 μg/mL). These findings suggest that a decreased ADAMTS-13 level and elevated VWF and VWFpp levels indicate the presence of hypercoagulability in patients with SSc. Changes in the VWF and VWFpp

Table 6. A Comparison Between Patients Having SSc With and Without Other CTD.*

|                         | SSc Without Other CTD: n = 152 | SSc With Other CTD: n = 81 | P Value |
|-------------------------|--------------------------------|---------------------------|---------|
| ADAMTS-13, %            | 85.57 (62.58, 101.23)           | 82.57 (59.27, 92.68)      | .28     |
| VWF, U/dL               | 136 (99, 162)                   | 140 (101, 194)            | .21     |
| VWFp, U/dL              | 114 (87, 157)                   | 131 (100, 171)            | .081    |
| d-dimer, μg/mL          | 0.50 (0.31, 1.16)               | 0.91 (0.41, 1.94)         | .026    |
| Soluble fibrin, μg/mL   | 0.90 (0.30, 3.00)               | 0.70 (0.30, 3.00)         | .92     |
| TM/eGFR, ng/mL²/min/1.73 m² | 0.0183 (0.1202, 0.2425)   | 0.1757 (0.1272, 0.2215)  | .79     |
| eGFR, ml/min/1.73 m²    | 75.7 (64.4, 86.5)               | 73.0 (60.3, 86.7)         | .43     |
| TRPG, mmHg              | 21 (16, 26)                     | 20 (18, 22)               | .87     |

Abbreviations: CTD, connective tissue disease; eGFR, estimated glomerular filtration rate; SSc, systemic sclerosis; TM, thrombomodulin; TRPG, tricuspid regurgitation pressure gradient; VWF, von Willebrand factor; VWFpp, von Willebrand factor propeptide.

*The data are presented as the median (Q1, Q3).

Table 7. A Comparison Between Patients Having SSc With Low and High D-Dimer Level.*

|                         | d-Dimer <1 μg/mL | d-Dimer ≥1 μg/mL | P Value |
|-------------------------|------------------|------------------|---------|
| lcSSc/dcSSc             | 83/30            | 54/17            | .73     |
| THE (acute or past)     | 8                | 24               | <.001   |
| Acute THE               | 0                | 10               | <.001   |
| Past THE                | 8                | 14               | .038    |
| ILD                     | 17               | 21               | .024    |
| Age, years              | 66.0 (57.0, 73.0) | 69.0 (60.0, 76.0) | .13     |
| ADAMTS-13, %            | 87.58 (70.03, 102.09) | 48.50 (37.50, 79.39) | .0010   |
| VWF, U/dL               | 127 (85, 156)    | 147 (132, 197)   | .012    |
| VWFp, U/dL              | 113 (85, 142)    | 156 (126, 188)   | .0020   |
| Soluble fibrin, μg/mL   | 0.40 (0.30, 2.20) | 4.45 (1.43, 9.13) | <.001   |
| TM/eGFR, ng/mL²/min/1.73 m² | 0.1675 (0.1154, 0.2251) | 0.1828 (0.1481, 0.2579) | .56     |
| eGFR, ml/min/1.73 m²    | 77.5 (63.7, 87.0) | 70.5 (63.2, 86.0) | .33     |
| TRPG, mmHg              | 21 (18, 25)      | 21 (19, 28)      | .65     |
| PT, seconds             | 11.6 (11.0, 12.3) | 11.6 (10.9, 12.4) | .80     |
| APTT, seconds           | 29.7 (27.6, 33.2) | 29.8 (27.6, 33.3) | .82     |
| CRP, mg/dL              | 0.060 (0.030, 0.17) | 0.59 (0.12, 3.28) | <.001   |
| LDH, IU/L               | 197 (179, 230)   | 220 (180, 291)   | .0090   |
| IgG, mg/dL              | 1239 (1037, 1498) | 1323 (1029, 1693) | .65     |
| Dose of steroid, prednisolone mg | 0 (0, 5) | 5 (0, 10) | .0010 |
| Duration of steroid, years | 0.11 (0, 8.1) | 5.6 (0, 11.8) | .0030 |
| Total dose of steroid, prednisolone mg | 1288 (0, 16620) | 13500 (0, 28560) | .0010 |

Abbreviations: APTT, activated partial thromboplastin time; CRP, C-reactive protein; dcSSc, diffuse cutaneous SSc; eGFR, estimated glomerular filtration rate; IgG, immunoglobulin G; ILD, Interstitial lung disease; lcSSc, limited cutaneous SSc; LDH, Lactate dehydrogenase; PT, prothrombin time; SSc, systemic sclerosis; THE, thrombotic event; TM, thrombomodulin; TRPG, tricuspid regurgitation pressure gradient; VWF, von Willebrand factor; VWFpp, von Willebrand factor propeptide.

*The data are presented as the median (Q1, Q3).
levels might result from vascular endothelial cell injury. The plasma levels of d-dimer in patients having SSc with other CTDs were higher than in patients having SSc without CTDs, possibly due to the presence of CTDs such as SLE or APS.

The plasma levels of VWFpp were significantly elevated in patients with dcSSc, suggesting the greater vascular endothelial cell injury in patients with dcSSc than in patients with lcSSc. The prevalence of ILD is known to be higher in patients with dcSSc than in patients with lcSSc. However, the pathogenesis of ILD has not been fully clarified. Surprisingly, the plasma levels of VWF and VWFpp were significantly higher in the patients with SSc with ILD than in those without ILD in the present study, suggesting a close relationship between ILD and vascular endothelial cell injury. Interestingly, very strong expression of VWF messenger RNA and the presence of immunoreactive VWF in the endothelial cells of murine small and microvessels of the lungs have been reported. The present results suggest the involvement of VWF and VWFpp in pulmonary endothelial cells in the pathogenesis of ILD in patients with SSc.

In conclusion, SSc carries a high risk of THE, especially in patients with other CTDs. Plasma hemostasis-related markers are closely related to ILD and THE. These markers are important as markers of organ involvement as well as THE.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported in part by a Grant-in-Aid from the Ministry of Health, Labor and Welfare and Research on intractable diseases of Japan for systemic sclerosis.

References

1. Ūnlü O, Zuiy S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol. 2016;3(2):75-84.
2. Wada H, Matsumoto T, Yamashita Y. Natural history of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Thromb Hemost. 2014;40(8):866-873.
3. Romero-Díaz J, García-Sosa I, Sánchez-Guerrero J. Thrombosis in systemic lupus erythematosus and other autoimmune diseases of recent onset. J Rheumatol. 2009;36(1):68-75.
4. Schoenfeld SR, Choi HK, Sayre EC, Aviña-Zubieta JA. Risk of pulmonary embolism and deep venous thrombosis in systemic sclerosis: a general population-based study. Arthritis Care Res (Hoboken). 2016;68(2):246-253.
5. Man A, Zhu Y, Zhang Y, et al. The risk of cardiovascular disease in systemic sclerosis: a population-based cohort study. Ann Rheum Dis. 2013;72(7):1188-1193.
6. Ngian GS, Sahhar J, Proudman SM, Stevens W, Wicks IP, Van Doornum S. Prevalence of coronary heart disease and cardiovascular risk factors in a national cross-sectional cohort study of systemic sclerosis. Ann Rheum Dis. 2012;71(12):1980-1983.
7. Mok MY, Lau CS. The burden and measurement of cardiovascular disease in SSc. Nat Rev Rheumatol. 2010;6(7):430-434.
8. Ihn H, Sato S, Fujimoto M, Takehara K, Tamaki K. Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. Br J Rheumatol. 1998;37(11):1188-1192.
9. Andersen GN, Caidahl K, Kazzam E, et al. Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthritis Rheum. 2000;43(5):1085-1093.
10. Cerinie MM, Valentini G, Sorano GG, et al. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum. 2003;32(5):285-295.
11. Denton CP, Bickerstaff MC, Shiwen X, et al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol. 1995;34(11):1048-1054.
12. Hettema ME, Zhang D, Stenstra Y, Smit AJ, Bootma H, Kallenberg CG. No effects of bosentan on microvasculature in patients with limited cutaneous systemic sclerosis. Clin Rheumatol. 2009;28(7):825-833.
13. Penn H, Howie AJ, Kingdon EJ, et al. Scleroderma renal crisis: patients characteristics and long-term outcomes. QJM. 2007;100(8):485-494.
14. Scully M. Thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome microangiopathy in pregnancy. Semin Thromb Hemost. 2016;42(7):774-779.
15. Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2000. Intern Med. 2010;49(1):7-15.
16. Habe K, Wada H, Itô-Habe N, et al. Plasma ADAMTS13, von Willebrand factor (VWF) and VWF propeptide profiles in patients with DIC and related diseases. Thromb Res. 2012;129(5):598-602.
17. Mori Y, Wada H, Okugawa Y, et al. Increased plasma thrombomodulin as a vascular endothelial cell marker in patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Clin Appl Thromb Hemost. 2001;7(1):5-9.
18. Habe K, Wada H, Matsumoto T, et al. Plasma ADAMTS13, von Willebrand factor (VWF) and VWF propeptide profiles in patients with connective tissue diseases and antiphospholipid syndrome. Clin Appl Thromb Hemost. 2017;23(6):622-630.
19. www.rheumatology.org/Portals/0/Files/2013%20ACR%20EULAR%20SSc%20Classification%20Criteria_Complete20%20article.pdf.
20. LeRoy EC, Black C, Fleischmajer F, et al. Scleroderma(systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202-205.
21. www.rheumatology.org/Portals/0/Files/1997%20Update%20of%201998%20Revised.pdf.
22. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344-347.
23. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403-407.
24. www.rheumatology.org/Portals/0/Files/2012%20ACR%20Sjogrens%20Classification%20Criteria%20v.pdf.
25. www.rheumatology.org/Portals/0/Files/2010_revised_criteria_classification_ra.pdf.
26. Steele R, Hudson M, Lo E, Baron M; Canadian Scleroderma Research Group. Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res (Hoboken). 2012;64(4):519-524.
27. Hinchcliffe M, Fischer A, Schiopu E, Steen VD; PHAROS Investigators. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol. 2011;38(10):2172-2179.
28. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005;129(1):93-100.
29. Ito-Habe N, Wada H, Matsumoto T, et al. Elevated von Willebrand factor propeptide for the diagnosis of thrombotic microangiopathy and for predicting a poor outcome. Int J Hematol. 2011;93(1):47-52.
30. Lee JJ, Pope JE. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. Arthritis Res Ther. 2014;16(5):435.
31. Yamaguchi T, Wada H, Miyazaki S, et al. Fibrin-related markers for diagnosing acute-, subclinical-, and pre-venous thromboembolism in patients with major orthopedic surgery. Int J Hematol. 2016;103(5):560-566.
32. Hasegawa M, Wada H, Miyazaki S, et al. The evaluation of fibrin-related markers for diagnosing or predicting acute or subclinical venous thromboembolism in patients undergoing major orthopedic surgery. Clin Appl Thromb Hemost. 2017.
33. Yamamoto K, de Waard V, Fears C, Loskutoff DJ. Tissue distribution and regulation of murine von Willebrand factor gene expression in vivo. Blood. 1998;92(8):2791-2801.
34. Wada H, Kobayashi T, Abe Y, et al. Elevated levels of soluble fibrin or D-dimer indicate high risk of thrombosis. J Thromb Haemost. 2006;4(6):1253-1258.